Literature DB >> 9676549

Management of specific symptom complexes in patients receiving palliative care.

E Bruera1, C M Neumann.   

Abstract

During the past 10 years there have been major changes in the management of the most common symptoms of terminal cancer. Opioid agonists remain the mainstay in the management of cancer pain. Slow-release preparations are currently available for several of these agents. The increased use of opioids has led to the recognition of opioid-induced neurotoxic effects and to the development of effective adjuvant drugs and other strategies to counteract these side effects. A number of drugs are available for the management of symptoms of cachexia, including corticosteroids and progestational drugs. Prokinetic drugs, either alone or in combination with other agents such as corticosteroids, are highly effective in the treatment of chronic nausea. For patients with asthenia, it should first be determined whether there are any reversible causes; if not, corticosteroids and psychostimulants may diminish the symptoms. Haloperidol, other neuroleptics and benzodiazepines may be required to manage hyperactive delirium. Oxygen and opioids are effective in treating dyspnea, whereas there is limited evidence that benzodiazepines provide any relief of this symptom. More research on the assessment and management of these devastating clinical symptoms of cancer is badly needed.

Entities:  

Mesh:

Year:  1998        PMID: 9676549      PMCID: PMC1229444     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  30 in total

1.  A controlled study of sustained-release morphine sulfate tablets in chronic pain from advanced cancer.

Authors:  T D Walsh; N MacDonald; E Bruera; K V Shepard; M Michaud; R Zanes
Journal:  Am J Clin Oncol       Date:  1992-06       Impact factor: 2.339

2.  Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study.

Authors:  P G Lawlor; K S Turner; J Hanson; E D Bruera
Journal:  Cancer       Date:  1998-03-15       Impact factor: 6.860

3.  Matching the clinical function and symptom status with the expectations of patients with advanced cancer, their families, and health care workers.

Authors:  H Neuenschwander; E Bruera; F Cavalli
Journal:  Support Care Cancer       Date:  1997-05       Impact factor: 3.603

4.  Subcutaneous morphine for dyspnea in cancer patients.

Authors:  E Bruera; T MacEachern; C Ripamonti; J Hanson
Journal:  Ann Intern Med       Date:  1993-11-01       Impact factor: 25.391

5.  Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine.

Authors:  E Bruera; J Pereira; S Watanabe; M Belzile; N Kuehn; J Hanson
Journal:  Cancer       Date:  1996-08-15       Impact factor: 6.860

6.  A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients.

Authors:  W Breitbart; R Marotta; M M Platt; H Weisman; M Derevenco; C Grau; K Corbera; S Raymond; S Lund; P Jacobson
Journal:  Am J Psychiatry       Date:  1996-02       Impact factor: 18.112

7.  Pain and its treatment in outpatients with metastatic cancer.

Authors:  C S Cleeland; R Gonin; A K Hatfield; J H Edmonson; R H Blum; J A Stewart; K J Pandya
Journal:  N Engl J Med       Date:  1994-03-03       Impact factor: 91.245

8.  Continuous intravenous infusion of morphine for severe dyspnea.

Authors:  M H Cohen; A J Anderson; S H Krasnow; S V Spagnolo; M L Citron; M Payne; B E Fossieck
Journal:  South Med J       Date:  1991-02       Impact factor: 0.954

9.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

Authors:  W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

10.  Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer.

Authors:  E D Bruera; T J MacEachern; K A Spachynski; D F LeGatt; R N MacDonald; N Babul; Z Harsanyi; A C Darke
Journal:  Cancer       Date:  1994-12-15       Impact factor: 6.860

View more
  7 in total

Review 1.  Palliative care for HIV disease in the era of highly active antiretroviral therapy.

Authors:  B Greenberg; R McCorkle; D Vlahov; P A Selwyn
Journal:  J Urban Health       Date:  2000-06       Impact factor: 3.671

Review 2.  Recent advances: palliative care.

Authors:  J A Billings
Journal:  BMJ       Date:  2000-09-02

3.  Bioethics for clinicians: 15. Quality end-of-life care.

Authors:  P A Singer; N MacDonald
Journal:  CMAJ       Date:  1998-07-28       Impact factor: 8.262

Review 4.  Management of Physical Symptoms in Patients with Advanced Cancer during the Last Weeks and Days of Life.

Authors:  Ahsan Azhar; David Hui
Journal:  Cancer Res Treat       Date:  2022-06-30       Impact factor: 5.036

5.  Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study.

Authors:  Catherine Weber; Thierry Merminod; François R Herrmann; Gilbert B Zulian
Journal:  Support Care Cancer       Date:  2007-10-17       Impact factor: 3.603

6.  Application of quality audit tools to evaluate care quality received by terminal cancer patients admitted to a palliative care unit.

Authors:  Li-Yun Tsai; In-Fun Li; Ching-Ping Liu; Wen-Hao Su; Tse-Yun Change
Journal:  Support Care Cancer       Date:  2008-01-15       Impact factor: 3.603

Review 7.  Assessing cancer pain.

Authors:  Shalini Dalal; Eduardo Bruera
Journal:  Curr Pain Headache Rep       Date:  2012-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.